We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Study on diagnostic efficacy of combined detection of serum CCL-18, p185 and SDF-1 in breast cancer.
- Authors
Jiebo Yin; Zhe Guan; Ben Wen; Yuluo Wu
- Abstract
This study aims to investigate the diagnostic efficacy of combined detection of serum C-C Motif Chemokine 18 (CCL-18), p185 and Stromal cell derived factor 1 (SDF-1) in breast cancer. 88 breast cancer patients admitted to our hospital were selected as study subjects. 88 healthy women who visited for a physical examination during the same period were selected as controls. Serum CCL-18, p185 and SDF-1 levels were measured. Combined detection and single detection in breast cancer diagnosis were compared in terms of sensitivity, specificity, accuracy, positive predictive value and negative predictive value. ROC (receiver operating characteristic) curves were drawn to further compare the differences between combined detection and single detection methods. CCL-18, p185 and SDF-1 in the cancer group were significantly higher than in the control group (p < 0.05). The area under the ROC curve of CCL-18, p185, SDF-1 and combined detection were 0.786 (95% Confidence Interval (CI): 0.717-0.854), 0.852 (95% CI: 0.788-0.916), 0.921 (95% CI: 0.883-0.958) and 0.962 (95% CI: 0.925-0.999), respectively. Sensitivity of combined detection was significantly higher than CCL-18 and p185 (p < 0.05). Specificity, accuracy and positive predictive value of combined detection were significantly higher than CCL-18, p185 and SDF-1 (p < 0.05). Compared with CCL-18 and p185, combined detection had a higher negative predictive value, which was statistically significant (p<0.05). Combined detection of serum CCL-18, p185 and SDF-1 is more effective at diagnosing breast cancer and is worth clinical application.
- Subjects
BREAST cancer diagnosis; BLOOD serum analysis; CHEMOKINES; STROMAL cell-derived factor 1; PREDICTION models
- Publication
European Journal of Gynaecological Oncology, 2024, Vol 45, Issue 3, p154
- ISSN
0392-2936
- Publication type
Article
- DOI
10.22514/ejgo.2024.058